Industry News (Joint Venture)

Agreement Signed To Produce Albumin in Transgenic Cows

Published in Blood Weekly, March 31st, 1997

Genzyme Transgenics Corp., Framingham, Massachusetts, announced that it has signed the largest transgenic commercialization agreement yet reached.

The agreement with Fresenius AG, Bad Homburg, Germany, provides for the development and commercialization of transgenic human serum albumin. Albumin is the most important protein involved in maintaining the balance of fluids in the blood.

Albumin regulates the transport of amino acids, fatty acids, hormones, drugs, and drug metabolites. Clinical uses include blood volume replacement during conditions of shock, serious burns, and other emergency medicine; during AIDS and cancer therapies; and during...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry